Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
8.095 USD -0.26 ( 3.11%)
Last update at 2026-11-17T21:00:00Z
VOLUME
5150
Market Cap
57.40M
P/E
6.01

Momentum Score

…

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.10
Low
8.29
High
52 Week Price Range
7.10
Low
14.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Daxor Corporation develops and commercializes blood-volume diagnostic systems that quantify total blood volume and red cell mass for use in cardiology, nephrology and hematology. Long-term growth may be supported by increased clinical adoption, improved reimbursement and broader evidence that blood-volume guided care can improve patient management, which could make its niche technology appealing.
Material risks include small commercial scale and liquidity, dependence on a single product, slow clinical uptake and reimbursement uncertainty that could constrain revenue expansion.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.36
Dividend Yield
-
Revenue TTM
0.03M
Revenue Per Share
0.01
Gross Profit TTM
0.03M
Debt / Equity
0.00
ROE
22.45%
Net Debt
0.11M
ROCE
25.15%
Diluted EPS TTM
1.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 9.17M 0.54M 0.28M 5.18M 4.75M
Net income 9.17M 0.54M 0.28M 5.18M 4.75M
Selling general administrative 0.33M 0.29M 0.31M 1.09M 0.99M
Selling and marketing expenses - - 0.63M - -
Gross profit 0.19M 2.13M 34.41M 6.31M 5.82M
Ebit - 0.62M -0.18M -0.86M -0.75M
Ebitda 9.19M 2.06M 0.33M 5.25M 4.75M
Depreciation and amortization - 1.44M 0.51M - -
Operating income 9.19M 0.62M 0.33M 5.25M 4.75M
Other operating expenses 8.68M 1.59M 34.26M 1.13M 1.07M
Interest expense 0.02M 0.09M 0.05M 0.07M 0.02M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.02M -0.09M -0.05M -0.07M -0.02M
Income tax expense - - -0.79M - -
Total revenue 0.50M 2.13M 34.59M 6.31M 5.82M
Total operating expenses -9.00M 1.59M 0.94M 1.13M 1.07M
Cost of revenue 0.31M - 0.18M - -
Total other income expense net -0.02M -0.09M -0.05M -0.07M -0.02M
Net income from continuing ops 9.17M 0.54M 0.28M 5.18M 4.75M
Net income applicable to common shares - - - 5.18M 4.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 46.01M 36.63M 34.87M 30.26M 24.98M
Other current assets - 0.01M -0.01M - 0.71M
Total liab 0.12M 0.84M 0.86M 1.29M 3.83M
Total stockholder equity 45.89M 35.79M 34.01M 28.97M 21.15M
Other current liab - - - - -0.09M
Common stock 0.06M 0.05M 0.05M 0.05M 0.05M
Capital stock 0.06M 0.05M 0.05M 0.05M 0.05M
Retained earnings 34.80M 25.63M 25.09M 24.79M 19.61M
Other assets - 36.63M 34.87M 0.02M 0.73M
Total current liabilities - 0.11M 0.10M 0.06M 0.09M
Net debt 0.11M 0.73M 0.76M 1.23M 3.02M
Short long term debt total 0.11M 0.73M 0.76M 1.23M 3.02M
Other stockholder equity 11.03M 10.11M -16.23M 4.13M 1.49M
Total current assets - 0.02M 0.03M 0.02M 0.03M
Long term investments 46.00M 36.61M 34.84M 30.22M 24.22M
Net tangible assets - - - 28.97M 21.15M
Net receivables - 0.01M 0.01M 0.02M 0.03M
Accounts payable 0.11M 0.11M 0.10M 0.06M 0.09M
Accumulated other comprehensive income 34.80M - 25.09M - -
Non currrent assets other 0.01M -36.61M -34.84M -30.22M -24.22M
Non current assets total 46.01M 36.61M 34.84M 30.22M 24.22M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - 0.00M 0.22M
Total cashflows from investing activities 1.18M 1.94M 2.75M - -
Net borrowings -0.73M -0.03M -0.47M -1.79M 2.85M
Total cash from financing activities -0.57M -0.03M 3.66M 0.06M 2.85M
Change to operating activities - - - -0.02M -0.02M
Net income 9.17M 0.54M 0.28M 5.18M 4.75M
Change in cash 0.00M 0.00M 0.00M -0.71M 0.09M
Begin period cash flow 0.00M 0.00M 0.00M 0.71M 0.62M
End period cash flow 0.00M 0.00M 0.00M 0.00M 0.71M
Total cash from operating activities -0.60M 0.03M -3.66M -0.77M -2.76M
Issuance of capital stock - - 4.53M 1.85M -
Change to account receivables 0.01M 0.00M 0.00M 0.01M -0.00M
Sale purchase of stock - - -0.40M - -
Other cashflows from financing activities - - -0.40M 4.08M 3.71M
Change to netincome - - - -5.94M -7.72M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.02M 0.01M 0.05M -0.01M 0.22M
Stock based compensation - - 0.63M - -
Other non cash items -9.80M -0.52M -4.62M -5.94M -7.72M
Free cash flow -0.60M 0.03M -3.66M -0.77M -2.76M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
DXR
Daxor Corporation
-0.26
3.11%
8.10 6.01 64.52 2150.71 1.27 5.64
ISRG
Intuitive Surgical Inc
-6.82
1.56%
430.93 43.30 31.35 12.25 7.35 11.63
ESLOF
EssilorLuxottica Société anonyme
-3.00
1.50%
197.00 44.84 27.62 4.07 2.49 3.71
ESLOY
Essilor International SA
-3.05
3.01%
98.21 41.68 27.25 3.94 2.45 3.71
BDX
Becton Dickinson and Company
-
-%
215.42 31.62 13.76 2.25 2.04 2.93

Profile*

Daxor Corporation

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

109 Meco Lane, Oak Ridge, TN, United States, 37830

865-425-0555

Name Title Year Born
Mr. Michael Richard Feldschuh Chairman, Pres & CEO 1969
Mr. Jonathan Adam Feldschuh Chief Scientific Officer & Director 1965
Mr. Robert J. Michel CPA, CPA, M.B.A. CFO, Chief Compliance Officer & Corp. Sec. 1957
Ms. Kathryn A. Kornafel VP of Marketing & Commercial Devel. NA
Mr. Guido Manzo VP of Sales NA
Ms. Jean Oertel Sr. VP Commercialization & Customer Experience NA
Mr. Michael Richard Feldschuh Chairman, President & CEO 1969
Mr. Robert J. Michel CPA, CPA, M.B.A. CFO, Chief Compliance Officer & Corporate Secretary 1957
Ms. Linda Cooper Vice President of Development & Operations NA
Ms. Kathryn A. Kornafel Senior VP of Marketing & Commercial Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…